This study examined the role of TGF-b1 in human keratinocyte malignancy. Two carcinoma-derived human oral keratinocyte cell lines, BICR 31 and H314, were selected on the basis of their known resistance to TGFb1-induced G 1 arrest, the presence of wild type TGF-b cell surface receptors and normal Ras. Smad 4 protein was undetectable in both cell lines, but Smad 2 and Smad 3 were expressed at levels comparable with a fully TGF-b responsive cell line, and treatment of the cells with TGF-b1 resulted in the phosphorylation of Smad 2. Treatment with exogenous TGF-b1 resulted in a failure to induce transcription from an arti®cial Smad-dependent promoter and a failure to down-regulate c-myc, but resulted in an up-regulation of AP-1 associated genes (Fra-1, JunB and ®bronectin). Transient transfection of Smad 4 into BICR 31 restored TGF-b1-induced growth inhibition and Smad-dependent transcriptional activation. Protracted treatment of cells with exogenous TGF-b1 resulted in the attenuation of cell growth in vitro. To over-express TGF-b1, both cell lines were transfected with latent TGF-b1 cDNA; neutralization studies of conditioned media demonstrated that whilst the majority of the peptide was in the latent form, a small proportion was present as the active peptide. Cells that overexpressed endogenous TGF-b1 grew more slowly in vitro compared to both the vector-only controls and cells that did not over-express the peptide. Orthotopic transplantation of cells that over-expressed endogenous TGF-b1 to the¯oor of the mouth in athymic mice resulted in marked inhibition of primary tumor formation compared to controls. Expression of a dominant-negative TGF-b type II receptor in cells that over-expressed endogenous TGF-b1 resulted in enhanced cell growth in vitro and diminished the tumor suppressor eect of the ligand in vivo, indicating that the endogenous TGF-b1 was acting in an autocrine capacity. The results demonstrate that over-expression of endogenous TGF-b1 in human malignant oral keratinocytes leads to growth inhibition in vivo and tumor suppression in vitro by mechanisms that are independent of Smad 4 expression and TGF-b1-induced G 1 arrest.
Introduction
Transforming growth factor-b is the generic name for a family of highly conserved ubiquitous peptides (TGFb1, -b2, -b3 in humans) that show a remarkable diversity of biological action. Most notably, TGF-b1 inhibits normal epithelial cell growth. TGF-b1 binds to type-II TGF-b cell surface receptors (TbR-II) which, in turn, transphosphorylate type-I receptors (TbR-I). Downstream targets of TbR-I include Smad 2 and Smad 3 (R-Smads) and after ligand-induced phosphorylation, they form complexes with Smad 4 (Co-Smad), which then translocate to the nucleus where they act as transcriptional regulators (de Caestecker et al., 2000) .
It is now generally accepted that all of the components of TGF-b signal transduction, namely, the ligand, the receptors, the signal transducers and their transcriptional targets constitute an important tumor suppressor pathway. In the mouse multistage model of skin carcinogenesis, for example, TGF-b1 is not detectable in chemically-induced papillomas with a high frequency of malignant progression (Glick et al., 1993) , loss of autocrine production of TGF-b1 facilitates tumor progression in keratinocytes with a targeted deletion of the TGF-b1 gene and in p53 null mice (Cui et al., 1994; Glick et al., 1994) and targeted expression of a dominant negative type II TGF-b receptor (DN-TbR-II) in mouse skin leads to an increase in carcinoma incidence and a decrease in tumor latency (Amendt et al., 1998) . As with a variety of other cancers, mutations of TbR-II (Garrigue-Antar et al., 1995; Wang et al., 1997) , TbR-I (Chen et al., 2001b) and Smad 4 genes (Kim et al., 1996) have been reported in human head and neck cancer and current thinking suggests that such anomalies provide tumor cells with a selective growth advantage. Defects of Smad 2 are uncommon and abnormalities of Smad 3 have not been reported in human tumors.
The functional signi®cance of defects in Smad gene expression is under intense scrutiny at the present time. To date, studies have focused on the role of Smad 4 in neoplasia not least because mutations of Smad 4 genes are common in pancreatic and colorectal cancers Schutte et al., 1996; Riggins et al., 1997) , haploid insuciency of Smad 4 is considered to be sucient for tumor initiation (Takaku et al., 1999; Xu et al., 2000) and bi-allelic loss of Smad 4 is thought to play a key role in tumor progression . Furthermore, the fact that replacement of Smad 4 restores TGF-b responsiveness in Smad 4 defective cells (De Winter et al., 1997; Le Dai et al., 1999) is compelling evidence that Smad 4 has the capacity to act as a tumor suppressor. More recently, however, alternative pathways have been identi®ed and it is now known that TGF-b1 can activate ®bronectin (Hocevar et al., 1999) , the 3TP-Lux reporter (Le Dai et al., 1999; Fink et al., 2001 ) and PAI-1 (Sirard et al., 2000) in Smad 4 de®cient cells. These studies demonstrate that TGF-b1 can elicit transcriptional responses in the absence of Smad 4 but they do not explore the functional signi®cance of Smad 4-independent pathways.
In the present study, we demonstrate that certain TGF-b1-induced transcriptional responses are retained in human oral keratinocytes that do not express Smad 4. By contrast, TGF-b1-induced regulation of cell cycle-related genes, the induction of Smad-dependent transcriptional activation and ligand-induced G 1 arrest is absent. Over-expression of endogenous TGF-b1 in these cells resulted in growth inhibition in vitro and tumor suppression in vivo. The results demonstrate for the ®rst time that Smad 4-independent pathways can mediate tumor suppression.
Results and discussion
Two human carcinoma-derived oral keratinocyte cell lines (BICR 31 and H314), established in dierent laboratories, were used as the parent cell lines in the present study. Previous work had shown that both BICR 31 and H314 expressed mutant p53 and contained wild type Ras (Yeudall et al., 1993 Burns et al., 1993; Clark et al., 1993) . In addition, BICR 31 and H314 were known to be resistant to TGF-b1-induced G 1 arrest despite expressing normal TbR-I and TbR-II (Prime et al., 1994; Malliri et al., 1996; Paterson et al., 2001) . A carcinoma-derived human oral keratinocyte cell line (H400) which was markedly growth inhibited by TGF-b1 (Prime et al., 1994) was used as a control.
Initially, the growth responses of the parent cell lines to exogenous TGF-b1 were examined. BICR 31 and H314 did not undergo growth arrest in response to 1 ng/ml TGF-b1 for 24 h (Figure 1a) , thereby con®rm-ing previous observations (Prime et al., 1994; Malliri et al., 1996) . In circumstances where the parent cell lines were treated with 2 ng/ml TGF-b1 for 10 ± 20 days, however, the growth rates of BICR 31 and H314 were signi®cantly slower than untreated controls (Figure 1b) . Similar data were obtained when a clonal cell line that did not over-express endogenous TGF-b1 (BICR31-b1-C9) was treated with exogenous TGF-b1 for extended time periods suggesting that the eect of the ligand on the heterogeneous parent lines was not due to the sensitivity of a sub-population of cells. Cell cycle analysis demonstrated that treatment of BICR 31 and H314 with 2 ng/ml TGF-b1 for 24 ± 96 h did not arrest the cells in any phase of the cell cycle (data not shown).
In order to obtain some insight into the above growth responses, certain TGF-b1 signal transduction pathways were examined. Immunoblot analysis of Smad 4 in BICR 31 and H314 indicated the absence of protein expression in both cell lines, but the protein was readily detectable in a fully TGF-b responsive cell line, H400 (Figure 2a ). In pancreatic and colorectal cancers, the absence of Smad 4 expression generally re¯ects a homozygous loss of the gene, or intragenic missense or nonsense mutations in one allele and deletion of the other (Korchynskyi et al., 1999; Wilentz et al., 2000a,b) . Southern and Northern blot analysis of BICR 31 and H314, using a full-length Smad 4 cDNA probe, showed no evidence of gene loss in either cell line and low levels of Smad 4 mRNA in H314 and BICR 31 (Figure 2a ). Studies are in progress to determine whether the absence of Smad 4 protein in BICR 31 and H314 is due to gene mutation(s) and/or decreased protein stability. At the present time, it is not possible to state categorically that there is a complete absence of Smad 4 protein expression in these lines because certain splice variants may have not been detected by the Smad 4-clone B8 monoclonal antibody that recognises an epitope within exon 5 (Pierreux et al., 2000) . However, endogenous levels of Smad 4 splice variants have not been detected by Western blotting, and sequences within exon 5 are essential for full transcriptional activity of Smad 4 (Pierreux et al., 2000) , suggesting that even if undetectable splice variants were expressed the functional consequences would be minimal. By contrast to Smad 4, Smad 2 and Smad 3 protein was readily detectable and expressed at similar levels in BICR 31, H314 and H400 (not shown) and treatment with TGF-b1 resulted in the rapid phosphorylation of Smad 2 in all cell lines, as determined by Western blot analysis using an antiphospho Smad 2 antibody ( Figure 2b ). The treatment of BICR 31 and H314 with exogenous TGF-b1 (2 ng/ ml for 24 h) resulted in a minimal increase in transcription (1.4 ± 2-fold) from an arti®cial TGF-binducible promoter containing four Smad binding elements (pSBE.Luc; Zawel et al., 1998) . The treatment of the fully responsive control cell line, H400 with TGF-b1 under similar conditions resulted in an 80-fold increase in luciferase activity. Further, the use of a reporter plasmid containing mutant Smad binding elements abolished TGF-b1-inducible luciferase activity ( Figure 2c ). Transient transfection of BICR 31 with Smad 4 cDNA restored TGF-b1-induced growth inhibition; treatment of the cells with exogenous TGFb1 (1 ng/ml for 24 h) resulted in a 25 ± 30% reduction in [ 3 H]-thymidine incorporation (data not shown) and treatment with 2 ng/ml TGF-b1 for 24 h caused an 18-fold increase in transcriptional activation of pSBE.Luc ( Figure 2c ). The fact that these responses were not restored to the level seen in the fully responsive cell line, H400, most probably re¯ects the low transfection were seeded into 24-well plates in keratinocyte growth medium (KGM consisted of DMEM : F12 (1 : 1), 10% (v/v) FBS, 0.6 mg/ml L-glutamine and 0.5 mg/ml hydrocortisone). At 60% con¯uence, the cells were treated with TGF-b1 (1 ng/ml TGF-b1 in KGM with reduced FBS (1%) for 24 hours; R&D Systems). Assays of [ 3 H]-thymidine incorporation were used to measure DNA synthesis, as described previously (Davies et al., 1997) . (b) Long term growth characteristics. BICR 31, H314 and BICR 31-b1-C9 were seeded into 60 mm dishes containing KGM and after 24 h, were treated with TGF-b1 (2 ng/ml TGF-b1 in KGM with reduced FBS (1%) for up to 20 days). The exogenous TGF-b1 and culture medium were changed at 1 and 2 day intervals, respectively. Cell counts were determined using a Coulter counter and the results were expressed as a percentage of untreated controls. Data points re¯ect the means (+ standard deviation) of triplicate wells or dishes; similar results were obtained in two repeat experiments. The data were examined statistically using the Student t-test with P50.05 considered to be statistically signi®cant eciency (20 ± 30%) of this cell line. Similar experiments could not be performed with H314 due to the fact that the eciency of transient transfection is extremely low (55%) with this cell line. Taken together, our results strongly indicate that Smad 4 is absent/non-functional in BICR 31 and H314 and that the remaining TGF-b signaling components are intact and functional in these cell lines. In a comparable way to the transcriptional activation of pSBE.Luc, c-myc expression was also unchanged in BICR 31 and H314 following treatment with 2 ng/ml TGF-b1 for 8 ± 24 h whereas c-myc expression was down-regulated in the control cell line (data not shown), as reported previously Malliri et al., 1996) . It is reasonable to conclude, therefore, that the absence of Smad 4 expression in BICR 31 and H314 resulted in To over-express TGF-b1, BICR31 and H314 cells were transfected with latent TGF-b1 cDNA in the expression vector pcDNA3; cells transfected with the vector alone served as controls. Transfected cells were selected in media containing 600 mg/ml G418 and later maintained in 200 mg/ml G418. Resistant colonies were pooled, expanded and designated BICR31-TGF-b1, H314-TGF-b1, BICR31-pcDNA3 and H314-pcDNA3, respectively. The TGF-b1-transfected cell lines were cloned to isolate cells expressing elevated (BICR31-b1-C10; H314-b1-C4; H314-b1-C6) or baseline (BICR31-b1-C9) levels of endogenous TGF-b1. To inhibit the autocrine eects of the over-expressed TGF-b1, BICR31-b1-C10 cells were transfected with a dominant-negative TGF-b type II receptor in the expression vector pcDNA3.1/Zeo (BICR31-b1-C10-DNTbRII) or the vector alone (BICR31-b1-C10-pcZeo). Transfected cells that were cultured in media containing 200 mg/ml G418 were further selected using 400 mg/ml Zeocin and later maintained in 200 mg/ml Zeocin. Details of transfection techniques, cloning and selection methods using these constructs have been reported previously (Davies et al., 1997; Paterson et al., 2001 ).
a Mean values with standard deviation in parenthesis. Autocrine TGF-b1 production was measured in conditioned medium by ELISA as described previously (Davies et al., 1997) . Samples of conditioned medium were assayed in triplicate in 3 ± 6 separate experiments. The data was examined statistically using the Student ttest with P50.05 considered to be statistically signi®cant.
b Cultured cells were grafted to the¯oor of the mouth of athymic mice (orthotopic transplantation) using techniques described previously (Davies et al., 1997) . After 60 days, the animals were killed and loco-regional spread of the primary tumor (haematogenous and lymphatic involvement) and metastatic dissemination (lymph nodes and lungs) were examined histologically. The results were expressed as the number of cases with either tumor invasion of blood vessels, lymphatic vessels or with metastases of the lymph nodes or lungs, per number of primary tumors. The results were examined statistically using Fisher's exact test with P50.05 considered to be statistically signi®cant. c Northern blot and ELISA analysis con®rmed that these cell lines over-expressed TGF-b1 to the same degree as BICR31-b1-C10.
d Degenerating primary tumors in grafts of H314-pcDNA3 (n = 2), H314-b1-C6 (n = 1) and BICR-b1-C10 (n = 4) lysates and the samples boiled. Proteins were separated on a 10% SDS ± PAGE gel and transferred to an Immobilon-P membrane (Millipore). The antibodies were mouse monoclonal anti-Smad 4-clone B8, (1 : 750; 1 h at room temperature; Santa Cruz) and goat anti-mouse horseradish peroxidase (1 : 1000; 45 min at room temperature; Sigma). Equal loading was con®rmed by probing with atubulin (1 : 20 000; 20 min at room temperature; Sigma). (b) Phosphorylation of Smad 2 following treatment with exogenous TGFb1, as determined by immunoblot analysis. BICR31, H314 and H400 were treated with 2 ng/ml TGF-b1 for 0 ± 1 h and protein samples were harvested and separated on SDS ± PAGE gels, as described in (a). The antibodies were rabbit anti-phospho Smad 2 Ser 465 ± 467 (1 : 500; 1 h at room temperature; Upstate Biotechnology) and goat anti-rabbit horseradish peroxidase, (1 : 1000; 45 min at room temperature; Sigma). Equal loading was con®rmed by probing with a-tubulin. (c) Transcriptional activation of pSBE.Luc following treatment of H400, H314, BICR 31 and BICR 31 transiently transfected with Smad 4 cDNA with exogenous TGF-b1. Cells were transfected with either the reporter plasmid pSBE.Luc containing four Smad binding elements or the plasmid pMBE.Luc containing mutant Smad binding elements (control), together with the Renilla luciferase control vector pRL-TK, as described previously (Paterson et al., 2001) . To express Smad 4 in BICR 31, the cells were transfected with Smad 4 cDNA in pcDNA3 or the vector alone (2 mg plasmid/well) 24 h prior to transfection with the reporter constructs. Cells were then treated with 2 ng/ml TGF-b1 for 20 h and luciferase activity was measured using the Dual Luciferase Assay (Promega), according to the manufacturer's instructions. Data points re¯ect the means (+ standard deviation) of triplicate wells. (d) JunB expression as determined by immunoblot analysis. BICR31 and H314 were treated with 2 ng/ml TGF-b1 for 0 ± 4 h and protein samples were harvested and separated on SDS ± PAGE gels, as described in (a). The antibodies were rabbit anti-JunB antibody (1 : 3000; 1 h at room temperature; Santa-Cruz) and goat anti-rabbit horseradish peroxidase, (1 : 1000; 45 min at room temperature; Sigma). Equal loading was con®rmed by probing with a-tubulin. (b) Growth of monolayer cultures of the parent cell line H314, the parent cells transfected with latent TGF-b1 (H314-b1-C4; H314-b1-C6) and the vector-only controls (H314-pcDNA3). (c) Growth of monolayer cultures of cells that over-expressed endogenous TGF-b1 (BICR31-b1-C10) transfected with dominant-negative TbR-II (BICR31-b1-C10-DN-TbRII) and the vector-only controls (BICR31-b1-C10-pcZeo). At 2 day intervals, the culture media were changed and cell counts were undertaken. Data points re¯ect the means (+ standard deviation) of triplicate dishes, similar results were obtained in two repeat experiments. The data were examined statistically using the Student t-test with P50.05 considered to be statistically signi®cant cell cycle related genes, such as the cyclin-dependent kinase inhibitor p15
INK4B
, have been shown to be strictly dependent on Smad 4 expression (Yan et al., 2000) . An alternative pathway, namely TGF-b-induced inhibition of p70 S6 kinase, has been described in EpH4 cells that leads to G 1 arrest independently of Smad dependent transcriptional control (Petritsch et al., 2000) . The fact that TGF-b does not induce G 1 arrest in BICR 31 and H314 suggests that this alternative pathway is absent or non-functional in these cells and that Smad-dependent mechanisms mediate TGF-b-induced G 1 arrest in these cell lines.
By contrast to the cell cycle-related genes, the treatment of BICR 31 and H314 with 2 ng/ml TGFb1 for 0 ± 4 h resulted in an increase in JunB and Fra-1 expression and, after 24 h, an increase in ®bronectin expression (Figure 2d ± f) . Smad responsive elements have been identi®ed in the promoters of several TGFb1-responsive genes, including JunB (Jonk et al., 1998; Derynck et al., 1998) and it is now recognized that Smad 3 and Smad 4 synergize with AP-1 complexes to mediate some TGF-b-induced transcription Wong et al., 1999; Qing et al., 2000) . The results of the present study demonstrate that TGF-b1-induced AP-1-dependent transcriptional responses in BICR 31 and H314 are retained in the absence of Smad 4 expression. The results parallel previous observations where TGF-b1-induced transcriptional responses are retained in Smad 4 de®cient cells (Hocevar et al., 1999; Le Dai et al., 1999; Sirard et al., 2000; Fink et al., 2001) . The situation, however, is now recognized as being more complex than ®rst envisaged. Smad proteins are recruited to speci®c promoters via a combination of Smad/DNA and Smad/transcription factor complexes and gene transcription is then regulated by the recruitment of coactivators and co-suppressors (de Caestecker et al., 2000) .
We wished to explore the functional eect of overexpression of TGF-b1 by the tumor cells (endogenous TGF-b1) in circumstances where there was loss of Smad 4 expression and cell cycle regulation but retention of some transcriptional responses. TGF-b1 cDNA was transfected into BICR 31 and H314 and the levels of TGF-b production were measured using ELISA (Table 1 ). There were no signi®cant dierences in the autocrine production of TGF-b1 between the parent cell lines, the vector-only controls for both H314 and BICR 31 and BICR31-b1-C9, a clonal cell line transfected with TGF-b1 cDNA which did not over-express the peptide. However, clonal cell lines were isolated which signi®cantly over-expressed endogenous TGF-b1 compared to both the parent cell lines and the vector only controls (H314-b1-C4, P50.0003; H314-b1-C6, P50.0002; BICR31-b1-C10, P50.0001). Neutralization studies, using conditioned media from the transfected cell populations of BICR 31 and H314, demonstrated that the majority of the peptide was in the latent form and a small proportion was present as the active peptide TGF-b1 (data not shown). The results support previous ®ndings that malignant oral keratinocytes have the capacity to activate latent TGF-b1 (Davies et al., 1997) .
To determine the eect of the over-expression of endogenous TGF-b1, the growth of BICR 31 and H314 was examined in vitro. There were no dierences in the growth rates of the parental BICR 31 cells, the vector-only control (BICR 31-pcDNA3) and BICR 31-b1-C9 which expressed baseline levels of endogenous TGF-b1. BICR 31-b1-C10, which over-expressed TGFb1 (13-fold), grew signi®cantly (day 4, P50.02) more slowly than BICR 31-b1-pcDNA3 and BICR 31-b1-C9 (Figure 3a) . Similarly, there were no dierences in the growth rates between the parental H314 cells and the vector-only control (H314-pcDNA3), but H314-b1-C4 and H314-b1-C6, cell lines which over-expressed endogenous TGF-b1 (2 ± 3-fold), grew signi®cantly (day 13, H314-b1-C4, P50.004; H314-b1-C6, P50.04) more slowly than the vector control ( Figure  3b ). Cell cycle analysis did not reveal any consistent variations in the cell cycle pro®les of the cell lines that over-expressed endogenous TGF-b1 compared to the control cell lines (data not shown), suggesting that the endogenous TGF-b1 was not causing the cells to accumulate in any phase of the cell cycle. Furthermore, there was no change in the growth inhibitory response of the cells or the regulation of transcription from pSBE.Luc in response to exogenous ligand after transfection with TGF-b1 cDNA and following increasing culture passage (data not shown). To investigate whether the over-expressed endogenous TGF-b1 that attenuated cell growth in vitro was acting in an intracellular or extracellular capacity, we transfected a dominant-negative TGF-b type II receptor (DN-TbR-II) into a cell line that overexpressed endogenous TGF-b1 (BICR 31-b1-C10). Examination of the growth rates in vitro demonstrated that BICR 31-b1-C10-DNRII grew signi®cantly faster (day 10, P50.006) than the vector-only controls (Figure 3c ). Taken together with the data showing detection of TGF-b1 by ELISA in conditioned culture media, the results suggest that the endogenous TGF-b1 was acting in an extracellular manner having been secreted and activated by the tumor cells prior to binding to TGF-b cell surface receptors and inhibiting cell proliferation. The ®ndings parallel the situation seen when the parent cell lines were treated with exogenous TGF-b1 for protracted time periods and suggest that the cellular response to exogenous and endogenous peptide was identical.
In order to determine whether our observations in vitro re¯ected tumor behaviour in vivo, cells were transplanted orthotopically to the¯oor of the mouth in athymic mice. The tumorigenicity of BICR 31, H314 and the transfected cell lines is shown in Table 1 . Transplantation of the parental cells (BICR 31, H314), vector only transfected cells (BICR 31 pcDNA3, H314-pcDNA3) and the clone that did not over-express TGF-b1 (BICR 31-b1-C9) resulted in 102/108 animals (94.4%) forming primary tumors at the site of inoculation. By contrast, cell lines that over-expressed endogenous TGF-b1 (BICR 31-b1-C10, H314-b1-C4, H314-b1-C6) formed signi®cantly fewer primary tumors than controls (BICR 31 controls vs BICR 31-b1-C10, P50.000001; H314 controls vs H314-b1-C4, P50.0005; H314 controls vs H314-b1-C6, P50.001), and those primary tumors that did form were invariably degenerate. There were no obvious dierences in the degree of cellular dierentiation of the tumors formed following transplantation of TGF-b1 over-expressing cells compared to the controls, as determined by H & E staining (BICR 31, moderatewell dierentiated; H314 poor-moderately dierentiated). The metastatic dissemination of the tumor cells re¯ected the incidence of primary tumors and occurred more commonly in the BICR 31 than the H314 derived cell lines. In grafts of cell lines that did not over-express endogenous TGF-b1 (H314, H314-pcDNA3, BICR 31, BICR 31-pcDNA3, BICR 31-b1-C9), there was a signi®cantly (P50.01) higher frequency of lymphatic dissemination and a higher frequency of lymph node tumor deposits than grafts of cell lines that over-expressed the ligand (H314-b1-C4, H314-b1-C6, BICR 31-b1-C10). Furthermore, transplantation of the cell line that over-expressed endogenous TGF-b1 and also expressed DN-TbR-II (BICR 31-b1-C10-DNRII) resulted in a signi®cant increase in the incidence of primary tumors compared to both the vector control (BICR 31-b1-C10-pcZeo, P50.01) and the parent cell line (BICR 31-b1-C10, P50.05). The data indicate that over-expression of endogenous TGFb1 results in marked tumor suppression of human malignant oral keratinocytes in vivo. The fact that this eect was partially blocked by the expression of dominant negative TbR-II strongly suggests that the endogenous TGF-b1 was acting in an autocrine capacity. Whether the endogenous TGF-b1 also had paracrine eects is not known because the animals containing the xenografts were killed at 60 days, by which time the tumors were either very small or degenerate.
The mechanisms underlying both the attenuated growth of the parent cell lines following protracted exposure to exogenous TGF-b1 and the tumor suppressor eects of endogenous TGF-b1 in vitro and in vivo are unknown. What is interesting is that these eects occurred in the absence of both Smad 4 expression and TGF-b1-induced G 1 cell cycle arrest in cells where some TGF-b1-induced transcriptional responses were retained. Smad 4-independent pathways that can transduce TGF-b1-mediated growth inhibitory responses and certain transcriptional responses have been identi®ed previously (Le Dai et al., 1999; Sirard et al., 2000; Fink et al., 2001 ) and may include SAPK/ JNK signaling (Hocevar et al., 1999) , Smad 4-related genes as identi®ed in Xenopus (Howell et al., 1999; Masuyama et al., 1999) or factors up-stream of Smad 4 such as Smad 3 Wong et al., 1999; Qing et al., 2000) . Interestingly, over-expression of a dominant-negative Smad 3 mutant not only impairs Smad-mediated signaling but also inhibits TGF-b1-dependent apoptosis, the latter being associated with activation of the AP-1 complex (Yamamura et al., 2000) . The present study, however, is the ®rst to show that Smad 4-independent pathways have a functional role in mediating TGF-b1-induced tumor suppression.
It is a widely held concept that defects of TGF-b signal transduction, either in terms of mutations of TbR-II (Garrigue-Antar et al., 1995; Wang et al., 1997) , TbR-I (Chen et al., 2001a) or Smad 4 genes (Kim et al., 1996) as seen in head and neck cancer, provide tumor cells with a selective growth advantage. The results of the present study show that TGF-b1 has the capacity to act as a potent tumor suppressor even in circumstances where there is an absence of Smad 4 expression.
